30-year story behind TGA approval

Posted 16 January 2025 PM

Teaming up with GSK, Professor Andrew Wilks and Dr Chris Burns achieved every scientist's dream last month after the TGA approved their drug discovery Omjjara, providing the first treatment for disease-related consequences of myelofibrosis.

The registration of Omjjara is the culmination of a thirty-year research story that began in Parkville, Melbourne in the 1980s, with Professor Wilks discovering the Janus kinase (JAK) proteins and then joining forces with Dr Burns to uncover the drug compound in 2005.

To see the whole article, please login